Söndag 11 Maj | 21:28:19 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-12 10:00 Bokslutskommuniké 2025
2025-11-05 10:00 Kvartalsrapport 2025-Q3
2025-07-22 10:00 Kvartalsrapport 2025-Q2
2025-05-15 N/A X-dag ordinarie utdelning DVYSR 0.00 SEK
2025-05-14 N/A Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-20 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2023-05-10 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Devyser Diagnostics utvecklar, tillverkar och säljer genetiska tester till laboratorier globalt. Produkterna används för DNA-tester inom onkologi, transplantation och ärftliga sjukdomar för att möjliggöra skräddarsydd cancerbehandling, diagnostik av ett stort antal genetiska sjukdomar och uppföljning av transplanterade patienter. Bolaget har sitt huvudkontor i Hägersten.
2023-03-01 16:46:42
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified product. Devyser Compact is a rapid genetic test for prenatal chromosome testing and the first of its type to be approved under the new more comprehensive regulation that came into force in May 2022. The original product was first launched in 2006 and is today the golden standard in prenatal testing in many European countries.

-We´re proud to announce the launch of our first IVDR product on the market. The launch is proof of our hard work to transition to IVDR, and our long-term commitment to quality and patient safety. To our customers it´s a reassurance that we will continue to provide safe and reliable products, says Theis Kipling, CCO, Devyser.  

Devyser Compact, provides efficient and sensitive detection of chromosomal abnormalities. In addition to detecting the most common syndromes, i.e., Down´s syndrome, the test includes patented technology for reliable diagnosis of Turner syndrome. The new version offers laboratories a safe and easy transition to IVDR. The Devyser test kit with a single tube solution is easy to use which minimizes hands-on time, analysis time and the risk of sample mix up.      

Devyser Compact will be available in all native English-speaking countries from March 1st. Other markets will have availability during March. The certification was issued by the notified body TÜV SÜD in August 2022 and covers Devyser Compact and Devyser´s quality management system.